Treatments in chronic rhinosinusitis with nasal polyps (CRSwNP) focus on reducing chronic type 2 inflammation. When intranasal corticosteroids, nasal saline irrigation, antibiotics, and oral steroids fail, patients move to surgery. Unfortunately, 40% of patients experience polyp regrowth following surgery.
New research in biologic therapy is showing promise. Inflammatory mediators IL-4, IL-5, IL-13, and IgE play key roles in CRSwNP. Targeting these specific inflammatory pathways may provide effective treatment options for refractory CRSwNP patients.
Dr Anju Peters discusses dupilumab, a biologic currently approved for CRSwNP, as well as other targeted biologics in development.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Targeted Treatment in Chronic Rhinosinusitis With Nasal Polyps - Medscape - Jul 13, 2020.
Comments